Blog Archives

Unbekannt oder ein Tabu über das man nicht spricht: Das Post-Finasterid Syndrom

13. Novemberr 2016 – Das Post-Finasterid Syndrom (PFS) beschreibt einen von Ärzten, Patienten und Medien verwendeten Begriff für einen Symptomkomplex mit anhaltenden sexuellen, neurologischen, mentalen und körperlichen Nebenwirkungen bei Patienten, die glatze-iiFinasterid, einen 5-alpha-Reduktase-Hemmer zur Behandlung von Haarausfall (androgene Alopezie) unter dem Markennamen Propecia oder Generika) oder einer vergrößerten Prostata (BPH) (unter dem Markenname Proscar oder Generika) eingenommen haben.

Read more ›

Tags: , , , , , , , , ,

Schlafstörungen, Gedächtnisverlust, sexuelle Dysfunktion, Depression und interstitielle Pneumopathie als mögliche Klasseneffekte von Arzneimitteln, welche die HMG CoA-Reduktase Inhibitoren Atorvastatin, Pravastatin, Fluvastatin, Simvastatin, Lovastatin, und Rosuvastatin als pharmakologisch aktive Wirkstoffe enthalten

2. Mai, 2010 – Gemäss einer kürzlichen Mitteilung vom 6. April 2010 hält es das Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) für erforderlich, die Produktinformationen aller HMG-CoA Reduktase-Inhibitoren (Statine: Atorvastatin, Pravastatin, Fluvastatin, Simvastatin, Lovastatin, Rosuvastatin) mit Hinweisen hinsichtlich der Risiken von Schlafstörungen, Gedächtnisverlust, sexueller Störungen, Depression und interstitieller Pneumopathie als möglichen Klasseneffekten zu ergänzen.

Read more ›

Tags: , , , , , , , , , , , , ,

Einheitliche Warnhinweise zum erhöhten Risiko für suizidales Verhalten bei jungen Erwachsenen

Im Bestreben, die betroffenen Patienten angemessen auf die Gefahren von Arzneimitteln und deren unerwünschten Nebenwirkungen aufmerksam zu machen, verpflichtet das BfArM pharmazeutische Unternehmen, welche Arzneimittel zur Behandlung von Depression in jungen Erwachsenen auf dem Markt haben, die Warnhinweise und Vorsichtsmassnahmen in den Fachinformationen bei Anwendung Suizid/Suizidgedanken oder klinische Verschlechterung per 1.

Read more ›

Tags: , , , , ,

Eine Hoffnung weniger für übergewichtige Patienten: Sistierung der Zulassung von Rimonabant [Acomplia]

Aufgrund eines Entscheids des Ausschusses für Humanarzneimittel (CHMP) der 
Europäischen Arzneimittelagentur EMA wurde die Zulassung von Rimonabant [Acomplia] in der europäischen 
Union ab 23. Oktober 2008 bis auf weiteres sistiert. In der Folge wurde die Zulassung von Rimonabant [Acomplia] auch in der Schweiz sistiert.  Rimonabant [Acomplia] war in der Schweiz seit März 2007 zugelassen als Zusatztherapie zu einer leicht hypokalorischen Diät und zu einer Bewegungstherapie für die Behandlung von adiposen Patienten (BMI  >

Read more ›

Tags: , , , , , , , , ,

thasso: zustände

thasso: neueste tweets

thasso: kürzliche kommentare

View my Flipboard Magazine.

thasso: kategorien

thasso: archive

thasso: einfacher chat

You must be a registered user to participate in this chat.

  • Newly discovered mutation could point to heart disease therapeutic target August 7, 2020
    New work led by Carnegie's Meredith Wilson and Steve Farber identifies a potential therapeutic target for clogged arteries and other health risks that stem from an excess of harmful fats in the bloodstream. Their findings are published by PLOS Genetics.
  • Genetic cause of congenital malformation discovered August 7, 2020
    Spontaneous mutations of a single gene are likely to cause serious developmental disorders of the excretory organs and genitalia. This is shown in an international study led by the University of Bonn and published in the journal Frontiers in Cell and Developmental Biology. The researchers also owe their findings to an unusual model organism: the […]
  • Novel approach reduces SCA1 symptoms in animal model August 7, 2020
    Research has shown that a mutation in the ATAXIN-1 gene leads to accumulation of Ataxin-1 (ATXN1) protein in brain cells and is the root cause of a rare genetic neurodegenerative disease known as spinocerebellar ataxia type 1 (SCA1). How healthy cells maintain a precise level of ATXN1 has remained a mystery, but now a study […]
  • Alport Syndrome: Research highlights link between genotype and treatment effectiveness August 7, 2020
    A large-scale analysis of the clinical characteristics of Alport syndrome in Japanese patients has revealed that the effectiveness of existing treatment with ACE inhibitors and/or angiotensin receptor blockers (RAS inhibitors) varies depending on the type of mutation in the syndrome's causal gene (COL4A5). RAS inhibitors are widely administered to patients with chronic kidney diseases as […]
  • Tasmanian devil research offers new insights for tackling cancer in humans August 6, 2020
    A rare, transmissible tumor has brought the iconic Tasmanian devil to the brink of extinction, but new research by scientists at Washington State University and the Fred Hutchinson Cancer Research Center in Seattle indicates hope for the animals' survival and possibly new treatment for human cancers.
  • checkmate 743 shows that dual immunotherapy, nivolumab + ipilimumab August 8, 2020
    The combination of first-line nivolumab and ipilimumab demonstrated an improvement of overall survival for patients with unresectable malignant pleural mesothelioma compared to platinum-based chemotherapy, according to research presented today at the International Association for the Study of Lung Cancer Virtual Presidential Symposium.
  • Phase 3 eXalt3 study shows significantly longer progression-free survival August 8, 2020
    Patients with non-small cell lung cancer (NSCLC) carrying anaplastic lymphoma kinase (ALK) gene alterations who received ensartinib experienced substantially longer progression-free survival than a matched group of patients who received crizotinib.
  • Addition of sintilimab to pemetrexed and platinum improved progression-free survival August 8, 2020
    The interim analysis of ORIENT-11, a phase III double-blind randomized trial has shown a nearly two-fold increase in progression-free survival with addition of sintilimab to chemotherapy in patients with advanced or metastatic non-squamous non-small cell lung cancer without EGFR or ALK genomic aberrations, according to research data presented today at the International Association for the […]
  • Heart attack case rates, treatment approaches, outcomes during COVID-19 pandemic August 7, 2020
    The increases and decreases in patient volume and associated changes in treatment experienced by individuals presenting with acute heart attack (myocardial infarction) before and immediately after the onset of the COVID-19 pandemic are examined in this observational study.
  • COVID recovery choices shape future climate August 7, 2020
    A new international study, led by the University of Leeds, warns that even with some lockdown measures staying in place to the end of 2021, without more structural interventions global temperatures will only be roughly 0.01°C lower than expected by 2030. However, the study estimates that including climate policy measures as part of an economic […]